Compare Stocks → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:DCPHNASDAQ:ENTANASDAQ:GTHXNASDAQ:INSMNASDAQ:MDGL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCPHDeciphera Pharmaceuticals$14.62-0.3%$15.65$9.90▼$17.73$1.18B0.39523,050 shs401,815 shsENTAEnanta Pharmaceuticals$12.92-1.7%$14.85$8.08▼$37.75$273.34M0.47256,395 shs90,289 shsGTHXG1 Therapeutics$3.99-4.8%$3.69$1.08▼$5.00$208.40M1.731.30 million shs343,795 shsINSMInsmed$25.81+2.1%$27.24$18.08▼$32.00$3.83B0.921.78 million shs2.74 million shsMDGLMadrigal Pharmaceuticals$204.65-6.3%$244.64$119.76▼$322.67$4.35B-0.47528,232 shs575,483 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCPHDeciphera Pharmaceuticals+0.62%-1.15%-3.68%+3.82%+2.44%ENTAEnanta Pharmaceuticals-2.16%-14.39%-9.87%+8.68%-63.84%GTHXG1 Therapeutics+2.20%+2.70%+4.75%+13.86%+57.52%INSMInsmed+4.81%-3.37%-4.39%-7.77%+33.63%MDGLMadrigal Pharmaceuticals+2.29%-6.27%-12.01%-2.03%-28.61%Thousands of investors use this no cost solution | Do you? (Ad)In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage"MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDCPHDeciphera Pharmaceuticals3.4103 of 5 stars3.40.00.03.82.71.70.6ENTAEnanta Pharmaceuticals3.7028 of 5 stars3.10.00.04.73.52.50.6GTHXG1 Therapeutics3.5802 of 5 stars3.32.00.03.82.90.80.6INSMInsmed4.0184 of 5 stars4.51.00.04.52.50.00.6MDGLMadrigal Pharmaceuticals4.6928 of 5 stars4.41.00.04.63.24.20.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCPHDeciphera Pharmaceuticals2.80Moderate Buy$23.0057.32% UpsideENTAEnanta Pharmaceuticals2.17Hold$19.3349.64% UpsideGTHXG1 Therapeutics2.50Moderate Buy$9.33133.92% UpsideINSMInsmed3.00Buy$44.9274.03% UpsideMDGLMadrigal Pharmaceuticals2.73Moderate Buy$356.7374.31% UpsideCurrent Analyst RatingsLatest MDGL, DCPH, ENTA, INSM, and GTHX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024INSMInsmedTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$48.004/22/2024MDGLMadrigal PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform$150.004/12/2024GTHXG1 TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.004/11/2024INSMInsmedBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$37.00 ➝ $40.004/1/2024INSMInsmedWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$55.003/20/2024DCPHDeciphera PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$14.00 ➝ $16.003/20/2024MDGLMadrigal PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$325.00 ➝ $405.003/15/2024MDGLMadrigal PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$405.00 ➝ $425.003/15/2024MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$338.00 ➝ $377.003/15/2024MDGLMadrigal PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$320.00 ➝ $375.003/15/2024MDGLMadrigal PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$351.00 ➝ $397.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCPHDeciphera Pharmaceuticals$163.36M7.23N/AN/A$4.38 per share3.34ENTAEnanta Pharmaceuticals$73.62M3.71N/AN/A$10.29 per share1.26GTHXG1 Therapeutics$82.51M2.53N/AN/A$0.68 per share5.87INSMInsmed$305.21M12.56N/AN/A($2.32) per share-11.13MDGLMadrigal PharmaceuticalsN/AN/AN/AN/A$20.53 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCPHDeciphera Pharmaceuticals-$194.94M-$2.29N/AN/AN/A-119.33%-49.44%-38.41%5/1/2024 (Estimated)ENTAEnanta Pharmaceuticals-$133.82M-$6.56N/AN/AN/A-187.77%-60.38%-32.29%5/13/2024 (Estimated)GTHXG1 Therapeutics-$47.97M-$0.95N/AN/AN/A-58.13%-106.04%-33.99%5/1/2024 (Confirmed)INSMInsmed-$749.57M-$5.34N/AN/AN/A-245.59%N/A-53.34%5/2/2024 (Estimated)MDGLMadrigal Pharmaceuticals-$373.63M-$19.94N/AN/AN/AN/A-219.39%-98.75%5/7/2024 (Confirmed)Latest MDGL, DCPH, ENTA, INSM, and GTHX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2024N/AMDGLMadrigal Pharmaceuticals-$6.06N/A+$6.06N/AN/AN/A 5/1/2024N/AGTHXG1 Therapeutics-$0.19N/A+$0.19N/AN/AN/A 2/28/202412/31/2023GTHXG1 Therapeutics-$0.27-$0.21+$0.06-$0.21$12.83 million$14.87 million 2/28/2024Q4 2023MDGLMadrigal Pharmaceuticals-$5.26-$5.68-$0.42-$5.68N/AN/A2/22/202412/31/2023INSMInsmed-$1.13-$1.28-$0.15-$1.28$82.15 million$83.70 million 2/7/2024Q1 2024ENTAEnanta Pharmaceuticals-$1.18-$1.58-$0.40-$1.58$22.74 million$18.00 million2/6/2024Q4 2023DCPHDeciphera Pharmaceuticals-$0.58-$0.54+$0.04-$0.54$45.93 million$48.30 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDCPHDeciphera PharmaceuticalsN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AGTHXG1 TherapeuticsN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCPHDeciphera PharmaceuticalsN/A3.803.59ENTAEnanta PharmaceuticalsN/A6.256.25GTHXG1 Therapeutics1.463.873.45INSMInsmedN/A4.123.75MDGLMadrigal Pharmaceuticals0.285.385.38OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCPHDeciphera Pharmaceuticals70.96%ENTAEnanta Pharmaceuticals94.99%GTHXG1 Therapeutics24.21%INSMInsmedN/AMDGLMadrigal Pharmaceuticals98.50%Insider OwnershipCompanyInsider OwnershipDCPHDeciphera Pharmaceuticals4.43%ENTAEnanta Pharmaceuticals13.64%GTHXG1 Therapeutics8.23%INSMInsmed4.60%MDGLMadrigal Pharmaceuticals23.92%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableDCPHDeciphera Pharmaceuticals35580.80 million77.22 millionOptionableENTAEnanta Pharmaceuticals14521.16 million18.27 millionOptionableGTHXG1 Therapeutics10052.23 million47.94 millionOptionableINSMInsmed373148.55 million141.72 millionOptionableMDGLMadrigal Pharmaceuticals37619.90 million15.14 millionOptionableMDGL, DCPH, ENTA, INSM, and GTHX HeadlinesSourceHeadlineMadrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6%marketbeat.com - April 24 at 7:14 PMMadrigal Statement on the Passing of Dr. Stephen Harrisonglobenewswire.com - April 24 at 4:00 PMMadrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024finance.yahoo.com - April 23 at 8:19 AMMadrigal Pharmaceuticals (NASDAQ:MDGL) Coverage Initiated by Analysts at Bank of Americaamericanbankingnews.com - April 23 at 3:34 AMUnited Healthcare’s Favorable Insurance Coverage of Rezdiffra Boosts Madrigal Pharmaceuticals Buy Ratingmarkets.businessinsider.com - April 22 at 8:53 PMMadrigal Pharmaceuticals (NASDAQ:MDGL) Earns Underperform Rating from Analysts at Bank of Americamarketbeat.com - April 22 at 8:29 AMKnights of Columbus Asset Advisors LLC Acquires 4,386 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)marketbeat.com - April 21 at 6:39 AMMadrigal Pharmaceuticals Welcomes New Employees with Equity Awardsmsn.com - April 20 at 6:14 AMMadrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Down 3.3%marketbeat.com - April 17 at 12:20 PMMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - April 16 at 4:05 PM7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024investorplace.com - April 15 at 7:52 AM211,488 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by AlpInvest Partners B.V.marketbeat.com - April 14 at 8:45 PMMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Rebecca Taub Sells 2,676 Sharesinsidertrades.com - April 11 at 6:37 AMMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Paul A. Friedman Sells 26,270 Shares of Stockinsidertrades.com - April 11 at 6:16 AMMadrigal Pharmaceuticals Launches Rezdiffra, a Pioneer in NASH Treatmentmsn.com - April 10 at 10:34 PM2 Under-the-Radar Growth Stocks to Considermsn.com - April 10 at 12:33 PM2 Under-the-Radar Growth Stocks to Considerfool.com - April 10 at 10:15 AMMoody Aldrich Partners LLC Sells 4,356 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)marketbeat.com - April 10 at 8:54 AMFirst ever MASH drug primed for big impact in USAthepharmaletter.com - April 9 at 4:17 PMMadrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosisfinance.yahoo.com - April 9 at 8:42 AMJames M. Daly Sells 32,489 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stockinsidertrades.com - April 9 at 4:22 AMMadrigal Pharmaceuticals, Inc.cnn.com - April 7 at 1:19 AMMadrigal Pharmaceuticals Awards Equity to New Employees as Inducementmsn.com - April 6 at 8:18 PMInsider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells 18,710 Shares of Stockinsidertrades.com - April 6 at 7:30 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines5 Semiconductor Giants: Navigating the Recent PullbackApril 12, 2024 9:10 AMView 5 Semiconductor Giants: Navigating the Recent PullbackWayfair: Strengthening Fundamentals or Just a Short Squeeze? April 2, 2024 7:45 AMView Wayfair: Strengthening Fundamentals or Just a Short Squeeze? 3 A.I. Stocks to Watch Out For Not Named NVIDIA April 23, 2024 7:00 AMView 3 A.I. Stocks to Watch Out For Not Named NVIDIA Can Netflix Stock Continue Into All-Time Highs After Earnings?April 18, 2024 7:32 AMView Can Netflix Stock Continue Into All-Time Highs After Earnings?Analysts Agree, This Could Be Tyson Stock’s Comeback YearApril 23, 2024 6:05 AMView Analysts Agree, This Could Be Tyson Stock’s Comeback YearAll Headlines Company DescriptionsDeciphera PharmaceuticalsNASDAQ:DCPHDeciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.Enanta PharmaceuticalsNASDAQ:ENTAEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.G1 TherapeuticsNASDAQ:GTHXG1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.InsmedNASDAQ:INSMInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Madrigal PharmaceuticalsNASDAQ:MDGLMadrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.